CHU-Hôtel-Dieu, Service d'Hépato-gastro-entérologie
Nantes, 44093, France
NCT Number: NCT02728063
The main objective of the study is to evaluate the effect on intestinal permeability of a supplementation with Lactibiane Tolérance® for 4 weeks (28 days) in patients suffering from irritable bowel syndrome (IBS) with diarrhea predominance.
Secondary objectives of the study are to evaluate the effects of supplementation with Lactibiane Tolérance® for 4 weeks (28 days) in patients suffering from IBS with diarrhea predominance on intestinal permeability, inflammation of the digestive tract, symptoms and comfort.
Single-center study in single open arms: 30 volunteer adults suffering from Irritable Bowel Syndrome (IBS) with diarrhea predominance and matching the criteria of inclusion and non-inclusion listed below.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Nantes, 44093, France
single-center pilot study in single open arm:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
probiotics
Time frame: at day 0 and day 28
Evolution between V1 and V2 of intestinal permeability evaluated by the lactulose-mannitol test according to the slope of urinary excretion of ingested lactulose percentage (calculated by linear regression) during the period representing the passage into the small intestine (2 to 4 hours after ingestion of lactulose-mannitol mixture).
Time frame: at day 0 and day 28
Evolution of slope percentages urinary excretion (UE) of ingested mannitol ([M]) (calculated by linear regression) during the period representing the Passage Into the Small Intestine (PISI) (2 to 4 hours (h) after ingestion of [L]-[M] mixture)
Time frame: at day 0 and day 28
Evolution of the ratio between the slopes of the UE percentages of lactulose ([L]) and [M] ingested during the PISI (2 to 4h after ingestion of lactulose-mannitol mixture)
Time frame: at day 0 and day 28
Evolution of the percentage of UE of [L] ingested on the excretion of ingested [M] during the period representing the PISI (2 to 4h after ingestion)
Time frame: at day 0 and day 28
Evolution of the UE percentage of [L] ingested on the UE of ingested [M] each lap of the period representing the PISI
Time frame: at day 0 and day 28
Evolution of he percent UE of [L] ingested on the UE of ingested [M] during the period representing the passage in the colon (between 4 and 5h after ingestion)
Time frame: at day 0 and day 28
Evolution of the percent UE of [L] ingested on the UE of ingested [M] during the period of 5h after ingestion
Time frame: at day 0 and day 28
Evolution of the UE percentage of [L] ingested on the UE of ingested [M] during the transition period representative of the stomach to the small intestine (between 0 and 2h after
Time frame: at day 0 and day 28
Evolution of the Percentage of UE of [L] and [M] ingested during the period representing the PISI (2 to 4h after ingestion)
Time frame: at day 0 and day 28
Evolution of the Percentage of UE of [L] and [M] ingested during a period of 5h after ingestion
Time frame: at day 0 and day 28
Evolution of the Percentage of UE of [L] and [M] ingested each 5h lap
Time frame: at day 0 and day 28
Evolution between V1 and V2 of inflammatory status by fecal calprotectin
Time frame: at week 0 and week 4
Time to onset of the first colored red stool after taking carmine red capsules (minutes)
Time frame: at week 0 and week 4
Average intensity of 7 days of the worst abdominal pain on Likert scale (11 points)
Time frame: at week 0 and week 4
Medium intensity of 7 days of abdominal discomfort on Likert scale (11 points)
Time frame: at week 0 and week 4
Stool consistency average of 7 days after Bristol Stool Scale (BSS)
Time frame: at week 0 and week 4
Mean daily stool frequency of 7 days after BSS quiz
Time frame: at day 0 and day 28
Evolution of the slope ( determined by linear regression ) and area under the curve of evolution of the concentration of sulfonic acid fluorescence (measured in the basolateral chamber ) over time (measured every 30 min for 3 hours )
Time frame: at day 0 and day 28
Evolution of the slope ( calculated by linear regression) and area under the curve of evolution of the concentration of Horse Radish Peroxidase (HRP) (measured in the basolateral chamber ) over time (measured every 30 minutes between 1 and 3 hours) .
PiLeJe
Industry
Effect of a Mixture of Probiotics, Lactibiane Tolérance® on Intestinal Permeability in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance
Acronym: PILATE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01896583
Diarrhea Predominant Irritable Bowel Syndrome
Phoenix, Arizona, United States
View Trial DetailsNCT02358694
Diarrhea Predominant Irritable Bowel Syndrome
Farmington, Connecticut, United States
View Trial DetailsNCT00616200
Diarrhea Predominant Irritable Bowel Syndrome
Chapel Hill, North Carolina, United States
View Trial DetailsNCT02111603
Diarrhea Predominant Irritable Bowel Syndrome
Rochester, Minnesota, United States
View Trial Details